Filing summary
Issuer and period: The supplied filing is Organovo Holdings, Inc.’s Form 10-K for the fiscal year ended March 31, 2021, filed June 15, 2021. It does not identify Vivosim Labs, Inc. as the registrant, and it reports annual results rather than a standalone 2020 Q4 period.
Business context
Organovo is an early-stage biotechnology company developing 3D human tissue models to study disease and identify drug targets. Its initial focus is inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, with plans to pursue drug discovery and eventually advance candidates toward clinical development. The company reported no revenue in fiscal 2021.
Following the suspension of its liver therapeutic tissue program in 2019 and a failed proposed merger with Tarveda, a board reconstitution in September 2020 preceded the restart of operations under this strategy.
Key financial metrics
| Metric | Year ended March 31, 2021 | Year ended March 31, 2020 |
|---|---|---|
| Revenue | $0 | $2.196 million |
| Operating expenses | $16.826 million | $23.671 million |
| Operating loss | $16.826 million | $21.475 million |
| Net loss | $16.826 million | $18.710 million |
| Net loss per share, basic and diluted | $2.44 | $2.80 |
| Cash used in operating activities | $13.323 million | $14.882 million |
| Cash and cash equivalents at period end | $37.364 million | $27.356 million |
| Working capital | $37.7 million | $26.5 million |
At March 31, 2021, total assets were $39.917 million, current liabilities were $0.721 million, and accumulated deficit was $296.291 million. The balance sheet reports no debt balance; the filing does not provide a separate debt metric. Gross margin is not meaningful because the company had no revenue or cost of revenue in fiscal 2021.
Changes versus the prior year
- Revenue fell to zero from $2.196 million after revenue-generating activities were halted during restructuring.
- Research and development expense declined 79% to $1.103 million as the company reduced staffing and activity; management said renewed development would increase R&D spending.
- SG&A expense declined 13% to $15.723 million. Fiscal 2021 included approximately $2.8 million of change-of-control severance charges and substantial noncash stock compensation.
- Operating cash use improved by about $1.6 million, while financing provided $23.835 million, primarily from at-the-market stock sales. The company issued 1,932,972 shares and received net proceeds of approximately $23.8 million.
- Net loss narrowed, partly because fiscal 2020 included $2.767 million of other income, including gains on asset sales and lease termination; fiscal 2021 other income was approximately $2,000.
Outlook, risks and unusual items
- Management expects fiscal 2022 operating expenses of $13 million to $15 million and believes available cash can fund operations for at least 12 months under its current plan. It expects to hire and rebuild R&D capacity; meaningful revenue is not expected in the foreseeable future.
- The company is an early-stage, unproven drug-discovery business with recurring losses and no identified drug candidates under its new model. Further financing may be needed; equity financing could dilute shareholders. The filing reports up to $128.6 million available under its shelf registration and approximately $28 million available through its ATM program at March 31, 2021.
- In June 2021, Cellink and affiliates challenged two bioprinter patents in inter partes review and filed a declaratory judgment action concerning several patents. The company estimated IPR costs of $850,000–$950,000; it said the patent action’s possible loss was not estimable.
- The September 2020 board changes triggered approximately $2.8 million of severance and a D&O insurance tail policy costing approximately $2.0 million gross, or $1.7 million net of returned premium, plus a new policy premium of approximately $0.8 million.
- COVID-19 had not, in management’s view, otherwise negatively affected operations to the filing date, but potential impacts include disruption to human-cell supplies, research progress, partners and access to capital.
- The company disclosed related-party ties and shared services, facilities and equipment with Viscient Biosciences, including common executives and intellectual-property arrangements.
Most important facts for investors to verify
- Confirm issuer and reporting period: the supplied document is Organovo Holdings’ FY2021 10-K, not a Vivosim Labs filing or a standalone 2020 Q4 report.
- Review the cash-burn assumptions behind management’s 12-month liquidity statement, the planned FY2022 expense range, and any financing after March 31, 2021.
- Track whether the company’s tissue models produce validated drug targets or candidates, and whether it secures collaborators or licensing partners.
- Follow the Cellink patent proceedings, associated costs and potential effects on the company’s intellectual-property position.
- Assess dilution from equity awards and ATM offerings, as well as governance and related-party arrangements with Viscient.